Alnylam Pharmaceuticals Inc (BSP:A1LN34)
R$ 84.33 -0.18 (-0.21%) Market Cap: 216.53 Bil Enterprise Value: 209.08 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 81/100

Q2 2024 Alnylam Pharmaceuticals Inc Earnings Call Transcript

Aug 01, 2024 / 12:30PM GMT
Release Date Price: R$75.49 (+11.87%)
Operator

Okay. Thank you for standing by and welcome to the Alnylam Pharmaceuticals Second Quarter 2020 for a conference call. At this time, all participants are in a listen-only mode and after the speakers' presentation, there will be a Q&A session. Please be advised that today's conference is being recorded. I would now like to turn to hand the conference over to the company for their remarks. Please go ahead.

Christine Lindenboom
Alnylam Phramaceuticals, Inc. - SVP of IR, Corporate COmmunications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors dot alnylam.com/events during today's call, as outlined on slide 2 of and will offer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot